Kallikrein [232-574-5]

Athens Research

Kallikrein [232-574-5]

9

Inhibitor Assay, Rheumatoid Arthritis, Complement System, Diabetes, Hereditary Angioedema , Coagulation

Research Use Only

≥95% by SDS-PAGE

Plasma kallikrein

Kallikrein is a family of secreted serine proteases with diverse physiological roles, most notably in the generation of bradykinin, a potent vasodilator involved in regulating blood pressure, inflammation, and pain. In plasma, kallikrein exists as an inactive precursor called prekallikrein, which is synthesized in the liver and activated by factor XII during the intrinsic coagulation pathway. Upon activation, kallikrein cleaves kininogen to release bradykinin, thereby increasing vascular permeability and contributing to inflammatory responses. Structurally, kallikreins share a conserved catalytic triad essential for their proteolytic activity and are stabilized by multiple disulfide bridges. Clinically, dysregulation of kallikrein activity is implicated in hereditary angioedema (HAE), a rare genetic disorder characterized by episodes of severe swelling due to excessive bradykinin production. Kallikrein inhibitors are used therapeutically to manage HAE by blocking bradykinin release and preventing angioedema attacks. Additionally, kallikreins play roles in blood clotting, skin desquamation, and are being studied for their involvement in cancer, kidney function, and other inflammatory diseases.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

≤-20°C

12352202